DK3142655T3 - Sammensætninger og fremgangsmåder til behandling af hjertefibrose med ifetroban - Google Patents
Sammensætninger og fremgangsmåder til behandling af hjertefibrose med ifetroban Download PDFInfo
- Publication number
- DK3142655T3 DK3142655T3 DK15792047.1T DK15792047T DK3142655T3 DK 3142655 T3 DK3142655 T3 DK 3142655T3 DK 15792047 T DK15792047 T DK 15792047T DK 3142655 T3 DK3142655 T3 DK 3142655T3
- Authority
- DK
- Denmark
- Prior art keywords
- ifetroban
- compositions
- methods
- cardiac fibrosis
- treating cardiac
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461994436P | 2014-05-16 | 2014-05-16 | |
US201462060198P | 2014-10-06 | 2014-10-06 | |
US201462078649P | 2014-11-12 | 2014-11-12 | |
US201562118896P | 2015-02-20 | 2015-02-20 | |
PCT/US2015/031395 WO2015176060A1 (en) | 2014-05-16 | 2015-05-18 | Compositions and methods of treating cardiac fibrosis with ifetroban |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3142655T3 true DK3142655T3 (da) | 2021-02-01 |
Family
ID=54480852
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK15792047.1T DK3142655T3 (da) | 2014-05-16 | 2015-05-18 | Sammensætninger og fremgangsmåder til behandling af hjertefibrose med ifetroban |
Country Status (9)
Country | Link |
---|---|
US (6) | US9693998B2 (da) |
EP (2) | EP3804717A1 (da) |
JP (1) | JP6273072B2 (da) |
CN (2) | CN107072972B (da) |
AU (2) | AU2015258805B2 (da) |
DK (1) | DK3142655T3 (da) |
ES (1) | ES2848348T3 (da) |
WO (1) | WO2015176060A1 (da) |
ZA (1) | ZA201607878B (da) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9693998B2 (en) | 2014-05-16 | 2017-07-04 | Cumberland Pharmaceuticals, Inc. | Compositions and methods of treating cardiac fibrosis with ifetroban |
US9833450B2 (en) * | 2015-02-19 | 2017-12-05 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders |
CN107708692A (zh) | 2015-06-30 | 2018-02-16 | 坎伯兰医药品股份有限公司 | Aerd/哮喘中的血栓烷受体拮抗剂 |
EP3448309A4 (en) * | 2016-04-27 | 2020-01-15 | Cumberland Pharmaceuticals Inc. | TREATMENT OF SYSTEMIC SCLEROSIS WITH IFETROBAN |
CN109152767B (zh) | 2016-05-11 | 2022-10-21 | 坎伯兰医药品股份有限公司 | 用血栓烷-a2受体拮抗剂治疗肌营养不良的组合物和方法 |
EP3569249A4 (en) * | 2016-12-27 | 2020-11-11 | Osaka University | MEDICAL COMPOSITION FOR TREATMENT OF CONTINUOUS HEART DISEASE |
JP2023519674A (ja) * | 2020-03-31 | 2023-05-12 | オグレットリー,マーティン | Covid-19の治療のためのトロンボキサンa2受容体拮抗薬の方法及び医薬組成物 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2809377A1 (de) | 1978-03-04 | 1979-09-13 | Boehringer Mannheim Gmbh | Phenoxyalkylcarbonsaeure-derivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel |
DE3000377A1 (de) | 1980-01-07 | 1981-07-09 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue sulfonamide, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel |
US4537981A (en) | 1981-11-09 | 1985-08-27 | E. R. Squibb & Sons, Inc. | 7-Oxabicycloheptane and 7-oxabicycloheptene compounds |
US4416896A (en) | 1982-05-17 | 1983-11-22 | E. R. Squibb & Sons, Inc. | 7-Oxabicyclopheptane substituted amino prostaglandin analogs useful in the treatment of thrombolytic disease |
US4663336A (en) | 1985-07-01 | 1987-05-05 | E. R. Squibb & Sons, Inc. | 7-oxabicycloheptane substituted diamide and its congener prostaglandin analogs useful in the treatment of thrombotic disease |
US4752616A (en) | 1987-06-29 | 1988-06-21 | E. R. Squibb & Sons, Inc. | Arylthioalkylphenyl carboxylic acids, compositions containing same and method of use |
US5066480A (en) | 1988-04-11 | 1991-11-19 | E. R. Squibb & Sons, Inc. | Method of preventing or reducing adverse reactions to protamine using a thromboxane a2 receptor antagonist |
US4839384A (en) | 1988-10-07 | 1989-06-13 | E. R. Squibb & Sons, Inc. | Method of inhibiting onset of or treating migraine headache using a thromboxane A2 receptor antagonist |
US5100889A (en) | 1989-04-03 | 1992-03-31 | E. R. Squibb & Sons, Inc. | 7-oxabicycloheptyl substituted heterocyclic amide or ester prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease |
JPH02273625A (ja) | 1989-04-14 | 1990-11-08 | Takeda Chem Ind Ltd | 高エンドセリン症予防・治療剤 |
US4977174A (en) | 1989-06-12 | 1990-12-11 | E. R. Squibb & Sons, Inc. | 7-oxabicycloheptane imidazole prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease |
US5128359A (en) | 1990-02-16 | 1992-07-07 | Laboratoires Upsa | Benzimidazole and azabenzimidazole derivatives which are thromboxane receptor antagonists, their methods of preparation |
ZA911453B (en) | 1990-03-19 | 1991-11-27 | Squibb & Sons Inc | Method of protecting against and/or treating ulcerative gastrointestinal conditions using a thromoboxane,a2 receptor antagonist and combination useful in preventing and/or treating ulcers and/or inflammation |
US5529992A (en) * | 1992-04-21 | 1996-06-25 | Curators Of The University Of Missouri | Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors |
US5399725A (en) | 1993-05-27 | 1995-03-21 | Bristol-Myers Squibb Co. | 7-oxabicycloheptane carboxylic acid prostaglandin analog intermediates useful in the preparation of anti-thrombotic and anti-vasospastic compounds and method for preparing same |
IL110376A (en) | 1993-08-02 | 1998-08-16 | Bristol Myers Squibb Co | Pharmaceutical preparations containing iftroban and methods for their preparation |
US5506248A (en) * | 1993-08-02 | 1996-04-09 | Bristol-Myers Squibb Company | Pharmaceutical compositions having good dissolution properties |
US6509348B1 (en) | 1998-11-03 | 2003-01-21 | Bristol-Myers Squibb Company | Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination |
US20030040534A1 (en) * | 2001-04-16 | 2003-02-27 | Hughes David E. | Enantiomers of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide |
JP2005533830A (ja) * | 2002-07-09 | 2005-11-10 | ビー.エム.アール.エイ. コーポレイション ベスローテン フェンノートシャップ | トロンボキサンa2受容体アンタゴニストおよびcox−2阻害剤の薬剤の組み合わせ |
US20060009496A1 (en) | 2004-06-15 | 2006-01-12 | Oates John A | Method for preventing hemoprotein and heme-mediated lipid peroxidation |
WO2006066008A2 (en) | 2004-12-14 | 2006-06-22 | Portola Pharmaceuticals, Inc. | Device and methods for identifying and treating aspirin non-responsive patients |
US7411071B2 (en) | 2005-01-13 | 2008-08-12 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
UA86528C2 (uk) | 2005-06-10 | 2009-04-27 | Донг-А Фармацевтікал.Ко., Лтд. | Засіб для попередження та лікування хвороб печінки, що містить похідну піразолопіримідинону |
US20090022729A1 (en) | 2007-04-13 | 2009-01-22 | Nigel Mackman | Methods and compositions for treating cardiac dysfunctions |
EP2144999A4 (en) * | 2007-05-03 | 2010-06-16 | Portola Pharm Inc | USE OF TP MODULATORS TO TREAT HEART CIRCULAR ILLNESSES IN ASPIRINSENSITIVES AND OTHER POPULATIONS |
US8299097B2 (en) | 2008-09-12 | 2012-10-30 | The Brigham And Women's Hospital, Inc. | Methods for treating inflammatory disorders |
WO2012009545A1 (en) | 2010-07-14 | 2012-01-19 | Cumberland Emerging Technologies, Inc | Methods of treating hepatorenal syndrome and hepatic encephalopathy with thromboxane-a2 receptor antagonists |
CA2832761A1 (en) | 2011-04-15 | 2012-10-18 | Vivabiocell S.P.A. | Immunodiagnostic method for diagnosing auto-immune systemic sclerosis (ssc) and systemic lupus erythematosus (sle) |
EP2766345B1 (en) * | 2011-10-14 | 2016-03-16 | Bristol-Myers Squibb Company | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
US9693998B2 (en) | 2014-05-16 | 2017-07-04 | Cumberland Pharmaceuticals, Inc. | Compositions and methods of treating cardiac fibrosis with ifetroban |
CN107708692A (zh) | 2015-06-30 | 2018-02-16 | 坎伯兰医药品股份有限公司 | Aerd/哮喘中的血栓烷受体拮抗剂 |
CN109152767B (zh) | 2016-05-11 | 2022-10-21 | 坎伯兰医药品股份有限公司 | 用血栓烷-a2受体拮抗剂治疗肌营养不良的组合物和方法 |
US20180050020A1 (en) | 2016-08-22 | 2018-02-22 | Cumberland Pharmaceuticals, Inc. | Ifetroban treatment of portal hypertension |
-
2015
- 2015-05-18 US US14/715,143 patent/US9693998B2/en active Active
- 2015-05-18 EP EP20209322.5A patent/EP3804717A1/en active Pending
- 2015-05-18 JP JP2017512891A patent/JP6273072B2/ja active Active
- 2015-05-18 AU AU2015258805A patent/AU2015258805B2/en active Active
- 2015-05-18 WO PCT/US2015/031395 patent/WO2015176060A1/en active Application Filing
- 2015-05-18 EP EP15792047.1A patent/EP3142655B1/en active Active
- 2015-05-18 CN CN201580036251.8A patent/CN107072972B/zh active Active
- 2015-05-18 ES ES15792047T patent/ES2848348T3/es active Active
- 2015-05-18 CN CN202010669751.8A patent/CN111728970A/zh active Pending
- 2015-05-18 DK DK15792047.1T patent/DK3142655T3/da active
-
2016
- 2016-11-15 ZA ZA2016/07878A patent/ZA201607878B/en unknown
-
2017
- 2017-05-30 US US15/608,507 patent/US10016399B2/en active Active
-
2018
- 2018-06-11 US US16/004,666 patent/US10314824B2/en active Active
- 2018-08-10 AU AU2018214135A patent/AU2018214135B2/en active Active
-
2019
- 2019-04-23 US US16/391,444 patent/US10583126B2/en active Active
-
2020
- 2020-01-27 US US16/752,933 patent/US10925860B2/en active Active
-
2021
- 2021-01-17 US US17/151,181 patent/US20210137895A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN111728970A (zh) | 2020-10-02 |
CN107072972A (zh) | 2017-08-18 |
US20190247364A1 (en) | 2019-08-15 |
US20180344704A1 (en) | 2018-12-06 |
EP3142655B1 (en) | 2020-12-02 |
ES2848348T3 (es) | 2021-08-06 |
US10314824B2 (en) | 2019-06-11 |
WO2015176060A1 (en) | 2015-11-19 |
JP6273072B2 (ja) | 2018-01-31 |
AU2015258805B2 (en) | 2018-05-10 |
CN107072972B (zh) | 2020-08-04 |
ZA201607878B (en) | 2019-09-25 |
US20150328190A1 (en) | 2015-11-19 |
EP3142655A4 (en) | 2017-12-20 |
JP2017522363A (ja) | 2017-08-10 |
US10583126B2 (en) | 2020-03-10 |
AU2015258805A1 (en) | 2016-12-01 |
EP3142655A1 (en) | 2017-03-22 |
US20200155512A1 (en) | 2020-05-21 |
US20210137895A1 (en) | 2021-05-13 |
AU2018214135A1 (en) | 2018-08-30 |
US9693998B2 (en) | 2017-07-04 |
US20170258771A1 (en) | 2017-09-14 |
AU2018214135B2 (en) | 2020-04-16 |
EP3804717A1 (en) | 2021-04-14 |
US10925860B2 (en) | 2021-02-23 |
US10016399B2 (en) | 2018-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3212226T3 (da) | Sammensætninger og anvendelsesfremgangsmåder til behandling af metaboliske lidelser | |
DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
DK3386484T3 (da) | Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler | |
DK3317284T3 (da) | Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse | |
DK3234133T3 (da) | Crispr-baserede sammensætninger og fremgangsmåder til anvendelse | |
DK3548033T3 (da) | Forbindelser og deres fremgangsmåde til anvendelse | |
DK3206497T3 (da) | Sammensætninger og fremgangsmåder til behandling af meibomsk kirtel-dysfunktion | |
DK3212778T3 (da) | Fremgangsmåder og sammensætninger til stabilisering af trans-splejsning af intein-modificerede proteaser | |
DK3557998T3 (da) | Sammensætninger, kompositioner og anvendelsesmetoder | |
DK3144001T3 (da) | Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf | |
DK3185868T3 (da) | Hidtil ukendte ULK1-inhibitorer og fremgangsmåder til anvendelse af samme | |
DK3119797T3 (da) | Raav-baserede sammensætninger og fremgangsmåder til behandling af amyotrofisk lateralsklerose | |
DK3209696T3 (da) | Fremgangsmåder og sammensætninger til diagnosticering og behandling af glioblastom | |
DK3393655T3 (da) | Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme | |
DK3394065T3 (da) | Tetrahydropyranyl-amino-pyrrolopyrimidinon og fremgangsmåder til anvendelse deraf | |
DK3204497T3 (da) | Terapeutisk hæmning af lactatdehydrogenase og midler dertil | |
DK3261644T3 (da) | Sammensætninger og fremgangsmåder til behandling af nethindenedbrydning | |
DK3189074T3 (da) | Sammensætninger og metoder til behandling og forebyggelse af inflammation | |
DK3331879T3 (da) | Benzazolforbindelser og fremgangsmåder til fremstilling og anvendelse af forbindelserne | |
DK3142655T3 (da) | Sammensætninger og fremgangsmåder til behandling af hjertefibrose med ifetroban | |
DK3142664T3 (da) | Sammensætninger og fremgangsmåder til behandling og diagnosticering af øjensygdomme | |
DK3194564T3 (da) | Trichodermasammensætninger og anvendelsesfremgangsmåder | |
DK3089971T3 (da) | Forbindelser og fremgangsmåder til anvendelse | |
DK3242947T3 (da) | Genterapi og elektroporese til behandling af maligniteter | |
DK3212776T3 (da) | Sammensætninger og fremgangsmåder i forbindelse med beta-glucosidase |